Stocks and Investing Stocks and Investing
Mon, March 4, 2013

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $200 on, Mar 4th, 2013


Published on 2024-10-25 02:05:01 - WOPRAI, Evan Seigerman
  Print publication without navigation


Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $185 to $200 on, Mar 4th, 2013.

Evan has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013


These are the ratings of the 2 analyists that currently disagree with Evan


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $187 on, Wednesday, February 27th, 2013
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013
Contributing Sources